Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Ovarian Neoplasms 19Breast Neoplasms 18Fallopian Tube Neoplasms 12Neoplasm Metastasis 10Triple Negative Breast Neoplasms 8Prostatic Neoplasms 8Neoplasms 7Endometrial Neoplasms 7Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Metastatic Castration-resistant Prostate Cancer 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Solid Tumors 3Neuroendocrine Tumors 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Glioma 3Glioblastoma 3Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Cholangiocarcinoma 2

Interventions

olaparib 1lutetium Lu 177 dotatate 1lanreotide 1fluorodopa F 18 1cabozantinib 1Sunitinib 1Random Allocation 1Octreotide 1Nivolumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × olaparib × 90 days × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡